Ivermectin was once known only as a humble antiparasitic drug—used to treat river blindness and intestinal worms. But today, it’s emerging as one of the most promising repurposed drugs in the fight against cancer.

What began as curiosity is now supported by a growing body of scientific research, preclinical trials, and real-world case reports. Across cancers—breast, colon, lung, brain, blood, and more—ivermectin is showing the ability to target cancer cells on multiple fronts.

The best part? It does this with a strong safety profile and minimal side effects, even at higher doses.

Ivermectin works by disrupting cancer cell metabolism, mitochondrial function, and signaling pathways like WNT/β-catenin, EGFR/AKT, and NF-κB—pathways known to drive cancer growth and survival.

Used strategically and precisely, ivermectin has become a cornerstone of my advanced Targeted Metabolic Cancer Therapy Protocols, often combined with other repurposed drugs (like Mebendazole, Fenbendazole, and Itraconazole), high-dose nutraceuticals, ketogenic diet, and oxygen therapy.

MECHANISMS OF ACTION

1- Kills Cancer Stem Cells (CSCs)
Cancer stem cells are a small but powerful subpopulation of tumor cells responsible for therapy resistance, metastasis, and relapse.
→ 2017 Dominguez-Gomez et al. found that ivermectin selectively inhibits breast cancer stem-like cells, reducing their ability to form new tumors. This suggests ivermectin targets the very “root” of cancer aggressiveness.

2- Induces Apoptosis (Programmed Cell Death)
Apoptosis is a natural, controlled process where unhealthy cells are eliminated — but cancer often blocks this process to survive.
→ 2020 Chen et al. showed ivermectin triggers mitochondrial dysfunction, leading to apoptosis in ovarian cancer cells.
→ 2022 Yan et al. further confirmed that ivermectin generates reactive oxygen species (ROS) and activates caspase enzymes, pushing cancer cells to self-destruct.
This dual mechanism makes it harder for cancer cells to resist dying.

3- Inhibits Metastasis (Cancer Spread)
Stopping metastasis is crucial because it’s often the real cause of death in cancer.
→ 2022 Jiang et al. demonstrated that ivermectin suppresses cancer cell migration and invasion by blocking the WNT/β-catenin pathway and disrupting integrin/FAK signaling — two major pathways cancers use to spread to new organs.

4- Suppresses Tumor Growth
Beyond killing individual cells, ivermectin shrinks entire tumors by shutting down survival pathways.
→ 2020 Chen et al. reported that ivermectin inhibits tumor progression by promoting the degradation of PAK1, a key oncogenic protein involved in cell growth and survival.

5- Reverses Chemotherapy Resistance
One of the biggest challenges in cancer treatment is that tumors often become resistant to standard chemotherapy.
→ 2019 Jiang et al. found that ivermectin resensitizes cancer cells to chemotherapy by targeting the EGFR/ERK/AKT/NF-κB pathway. This means ivermectin can make existing treatments work better and overcome drug resistance.

6- Enhances Immune Response Against Tumors
Some tumors are “cold,” meaning they don’t trigger a strong immune attack.
→ 2021 Dougan et al. showed that ivermectin can turn “cold” tumors into “hot” ones by promoting immune cell infiltration and activation — particularly important in Triple Negative Breast Cancer (TNBC), a cancer subtype with limited treatment options.

CANCER TYPES STUDIED WITH IVERMECTIN

1. Breast Cancer

• TNBC: Ivermectin enhances immune infiltration and response to checkpoint inhibitors.
• Estrogen-positive: Suppresses proliferation and induces cell cycle arrest.

2. Ovarian Cancer

• Targets Akt/mTOR and HIF-1α pathway, suppressing cell survival and invasion. (Chen et al 2020)

3. Prostate Cancer

• Inhibits AR signaling, sensitizes to androgen deprivation therapy. (Li et al 2021)

4. Glioblastoma

• Crosses blood-brain barrier, kills glioma stem cells, and enhances radiation. (Zhang et al 2020)

5. Colon Cancer

• Blocks WNT/β-catenin signaling. (Dou et al 2019)

6. Leukemia

• Induces apoptosis in leukemia cells and reverses drug resistance. (Ref: International J of Cancer 2017)

7. Lung, Liver, Melanoma, Pancreatic

• Ivermectin has been shown to reduce tumor volume in mouse models across these cancer types.

DOSING STRATEGY IN METABOLIC PROTOCOLS

Standard therapeutic range:

• 0.2–2 mg/kg/day, one dose or split into two doses.
  https://pmc.ncbi.nlm.nih.gov/articles/PMC7505114/
  https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1251-7
• Taken with meals and fat (like full-fat milk or coconut oil) for better absorption.
• Combined with Fenbendazole or Mebendazole for maximum effect.
• Often stacked with Curcumin, Omega-3, Vitamin D3, Berberine, and Hyperbaric Oxygen for synergy.

MY TAKE

Ivermectin is one of the most powerful repurposed drugs in the modern cancer arsenal. Its impact is real, and it goes far beyond theory. I’ve seen tumors shrink, markers drop, and “incurable” cases reverse—all with properly dosed ivermectin.

• It’s not magic. It’s metabolic medicine.
• It’s not hype. It’s cellular biochemistry.
• The results speak for themselves.

Preclinical Studies (In Vitro and In Vivo)

1. Juarez, M., et al.
   The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.
   American Journal of Cancer Research, 2018.
   This comprehensive review summarizes in vitro and in vivo evidence demonstrating ivermectin’s antitumor effects across various cancer types.
2. Wang, J., et al.
   Ivermectin, a potential anticancer drug derived from an antiparasitic agent.
   Biochemical and Biophysical Research Communications, 2021.
   This study highlights ivermectin’s powerful antitumor effects, including inhibition of proliferation, metastasis, and angiogenesis in various cancer cells.
3. Hashimoto, H., et al.
   Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines.
   Drug Discovery & Therapy, 2009.
   This research demonstrates ivermectin’s ability to inhibit PAK1 kinase, thereby suppressing the growth of ovarian cancer and NF2 tumor cell lines.
4. Draganov, D., et al.
   Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via ivermectin induces a non-apoptotic and inflammatory form of cancer cell death.
   Scientific Reports, 2015.
   The study reveals that ivermectin modulates purinergic signaling pathways, leading to a unique form of cancer cell death.
5. Nambara, S., et al.
   Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer.
   Oncotarget, 2017.
   This paper discusses ivermectin’s role in inhibiting YAP1 expression, resulting in suppressed gastric cancer cell proliferation.
6. Gallardo, M., et al.
   Ivermectin induces autophagy-dependent cell death through dephosphorylation of TFE3 in melanoma cells.
   Biochemical and Biophysical Research Communications, 2020.
   The research indicates that ivermectin triggers autophagy-dependent cell death in melanoma cells by affecting TFE3 phosphorylation.

🧬 Clinical Observations and Case Reports

1. Juarez, M., et al.
   The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.
   American Journal of Cancer Research, 2018.
   This review includes discussions on clinical observations where ivermectin has been used in cancer patients, noting positive outcomes without significant toxicity.
2. Wang, J., et al.
   Ivermectin, a potential anticancer drug derived from an antiparasitic agent.
   Biochemical and Biophysical Research Communications, 2021.
   The study references case reports and clinical experiences utilizing ivermectin doses up to 2 mg/kg/day in cancer patients, observing positive outcomes without significant toxicity.